

MINI-REVIEW

The GSK3 hypothesis of Alzheimer's disease

Claudie Hooper, Richard Killick and Simon Lovestone

*King's College London, MRC Centre for Neurodegenerative Research, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, UK***Abstract**

Glycogen synthase kinase 3 (GSK3) is a constitutively active, proline-directed serine/threonine kinase that plays a part in a number of physiological processes ranging from glycogen metabolism to gene transcription. GSK3 also plays a pivotal and central role in the pathogenesis of both sporadic and familial forms of Alzheimer's disease (AD), an observation that has led us to coin the 'GSK3 hypothesis of AD'. According to this hypothesis, over-activity of GSK3 accounts for memory impairment, tau hyper-phosphorylation, increased β -amyloid

production and local plaque-associated microglial-mediated inflammatory responses; all of which are hallmark characteristics of AD. If our 'GSK3 hypothesis of AD' is substantiated and GSK3 is indeed a causal mediator of AD then inhibitors of GSK3 would provide a novel avenue for therapeutic intervention in this devastating disorder.

Keywords: Wnt, insulin, tau, β -amyloid, memory, inflammation.

J. Neurochem. (2008) **104**, 1433–1439.

Alzheimer's disease (AD) is a neurodegenerative disorder defined by progressive memory loss and cognitive impairment and at the molecular level by the presence of neurofibrillary tangles (NFTs) and insoluble β -amyloid ($A\beta$) plaques (Hardy 2006) that are associated with activated microglia (Vehmas *et al.* 2003). NFTs are composed of hyper-phosphorylated forms of the microtubule-associated protein tau, whereas $A\beta$ is derived from the proteolytic cleavage of β -amyloid precursor protein (APP). Early onset forms of Familial Alzheimer's disease (FAD) typically present before the age of 65 and have been linked to mutations in APP, presenilin-1 (PS-1) and presenilin-2 (PS-2). Mutations in these genes adversely affect APP processing and result in the increased production of insoluble $A\beta$ and its deposition into plaques.

β -Amyloid precursor protein, presenilin and tau are undoubtedly pivotal to understanding the pathogenesis of AD and there are as yet no convincing refutations of the classical amyloid cascade hypothesis of AD, which postulates that, $A\beta$ over-production leads to the pathogenic hyper-phosphorylation of tau resulting in the formation of neurofibrillary tangles (NFTs) and neurodegeneration. However, this hypothesis raises as many questions as it does answers. What regulates the processing of APP in sporadic AD as opposed to those very few families harboring APP or PS mutations? Which species of $A\beta$ ($A\beta_{42}$, $A\beta_{56}$, aggregated fibrillar $A\beta$ or soluble oligomeric $A\beta$, intracellular $A\beta$ or extracellular $A\beta$) is neurotoxic and how exactly does $A\beta$ induce tau hyper-phosphorylation and does this lead to tau

aggregation, neurotoxicity and loss of neuronal function? These are not idle questions, drug development in the AD field has concentrated very heavily on trying to alter APP processing, but developing alternative approaches is almost certainly going to be necessary for the effective treatment of this devastating and costly condition. We propose that glycogen synthase kinase-3 (GSK3) plays a leading role in the cascade of events that culminate in AD as this kinase is involved in the mechanisms underlying learning and memory, in the hyper-phosphorylation of tau, in the increased production of $A\beta$ from APP and also in local cerebral inflammatory responses.

GSK3 and cell signaling

There are two GSK3 genes from which GSK3 α and GSK3 β are derived. GSK3 β also exists as longer splice variants (Mukai *et al.* 2002; Schaffer *et al.* 2003). GSK3 α and GSK3 β are ubiquitously expressed, constitutively active, proline-directed serine/threonine kinases involved in a variety of cellular processes including glycogen metabolism (Welsh and Proud

Received October 19, 2007; revised November 21, 2007; accepted December 10, 2007.

Address correspondence and reprint requests to Simon Lovestone, King's College London, MRC Centre for Neurodegenerative Research, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. E-mail: S.Lovestone@iop.kcl.ac.uk

Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

1993), gene transcription (Troussard *et al.* 1999), apoptosis (Turenne and Price 2001) and microtubule stability (Anderton *et al.* 2001; Brion *et al.* 2001). Insights from mouse models suggest that the GSK3 isoforms exhibit tissue specific physiological functions. GSK3 β knock-out mice die *in utero* (Hoeflich *et al.* 2000), whereas GSK3 α knock-out mice are viable and display improved glucose tolerance in response to glucose load and elevated hepatic glycogen storage and insulin sensitivity (MacAulay *et al.* 2007).

GSK3 activity is modulated by insulin and Wnt signaling, both pathways act in a negative regulatory manner. Many, but not all GSK3 substrates require pre-phosphorylation (priming) before phosphorylation by GSK3 can occur, so in both health and disease the activity of the priming kinase might limit GSK3 activity. Insulin signaling leads to the activation of PI3-kinase and subsequently the activation of acutely transforming retrovirus Akt8 in rodent T cell lymphoma (Akt otherwise known as protein kinase B), which in turn phosphorylates free cytoplasmic GSK3 β and GSK3 α at serine (Ser) residues 9 and 21, respectively (Saltiel and Kahn 2001; Lizcano and Alessi 2002). Regulatory serine phosphorylation results in the generation of an intra-molecular pseudo-substrate, which blocks part of the active site preventing the enzymatic activity of GSK3 towards primed substrates. This in turn leads to the de-phosphorylation of downstream substrates such as glycogen synthase and eukaryotic protein synthesis initiation factor-2B (eIF-2B), which elicits an increase in glycogen and protein synthesis. GSK3 can also be phosphorylated at Ser9/21 by p70 ribosomal S6 kinase-1 (S6K1) and by 90 kDa ribosomal protein S6 kinase (RSK), a downstream mediator of mitogen-activated protein kinase (MAPK) signaling (Doble and Woodgett 2003).

In addition to regulatory Ser phosphorylation, GSK3 β and GSK3 α activity can be regulated by tyrosine (Tyr) phosphorylation at residues 216 or 279, respectively. Under physiological conditions, GSK3 is phosphorylated at these sites and increases in Tyr phosphorylation augment GSK3 activity. However, regulation of GSK3 at Tyr 216/279 is perhaps less common than regulation at Ser9/21 (Bhat *et al.* 2000; Bijur and Jope 2001).

Wnt signaling regulates GSK3 activity by physically displacing complexed GSK3 from a number of regulatory binding partners consequently preventing the phosphorylation and degradation of β -catenin. In the absence of Wnt, the signaling pool of β -catenin is maintained at low levels through degradation (Dale 1998; Huelsken and Behrens 2002; Nusse 2005). β -catenin is targeted for ubiquitination by the β -transducin repeat containing protein (β TrCP) and is then degraded by the proteasome. β -catenin is phosphorylated by the serine/threonine kinases casein kinase 1 (CK1) and GSK3 β . Phosphorylation of β -catenin occurs in a multi-protein complex (the destruction complex), comprising axin, adenomatous polyposis coli protein and diversin. Upon receipt of a Wnt signal, dishevelled prevents degradation of

β -catenin through the recruitment of GSK3 binding protein (GBP)/Frat-1, which displaces GSK3 β from the destruction complex. Stabilized β -catenin enters the nucleus and associates with T cell factor/lymphoid enhancer factor transcription factors, leading to the transcription of Wnt target genes, such as *cyclin D1*, *PPAR δ* and *twin*. Recently, GSK3 α in addition to GSK3 β , has been shown to function in the destruction complex and the Wnt signaling pathway, suggesting that this enzyme is equally as important in Wnt biology as is GSK3 β (Asuni *et al.* 2006; Doble *et al.* 2007).

The role of GSK3 in AD

The evidence that GSK3 plays a central role in AD and that its deregulation accounts for many of the pathological hallmarks of the disease in both sporadic and familial AD cases, has led us to formulate the 'GSK3 hypothesis of AD.' Evidence from our group and others suggests that GSK3 is intimately involved in the hyper-phosphorylation of tau, memory impairment, the increased production of A β and in inflammatory responses (Fig. 1). GSK3 also reduces acetylcholine synthesis, which is in accordance with the cholinergic deficit present in AD (Hoshi *et al.* 1996). Moreover, GSK3 is a key mediator of apoptosis (Turenne and Price 2001) and thereby might directly contribute to neuronal loss in AD.

Indeed, if GSK3 is central to AD pathogenesis then one would expect evidence for increased activity of this enzyme in AD. However, there is little such evidence, as it is technically difficult, if not impossible, to measure enzymatic activity in post-mortem brain tissue. Nevertheless, indirect evidence does support the role of GSK3 in disease. GSK3 has been shown to co-localize with dystrophic neurites and NFTs (Yamaguchi *et al.* 1996; Imahori and Uchida 1997; Pei *et al.* 1997). Active GSK3 appears in neurons with pre-tangle changes (Pei *et al.* 1999) and there is increased GSK3 activity in the frontal cortex in AD as evidenced by immuno-blotting for GSK3 phosphorylated at Tyr216 (Leroy *et al.* 2007). Furthermore, GSK3 expression is up-regulated in the hippocampus of AD patients (Blalock *et al.* 2004) and in post-synaptosomal supernatants derived from AD brain (Pei *et al.* 1997), although the latter study reports that there is not an increase in GSK3 enzymatic activity. GSK3 expression is also up-regulated in circulating peripheral lymphocytes in both AD and in mild cognitive impairment (Hye *et al.* 2005). It has recently been reported that a polymorphism in the GSK3 promoter is a risk factor for late onset AD (Mateo *et al.* 2006), which might account for alterations in GSK3 expression in disease. Collectively, these findings suggest that GSK3 activity might be increased in AD, through changes in its phosphorylation state as well as expression levels, although we acknowledge that direct evidence for this is still limited at present and some studies find no change in GSK3 activity (Pei *et al.* 1997) or reduced GSK3 activity (Swatton *et al.* 2004) in AD.

Genetic and epidemiological studies indicate that GSK3 is deregulated in AD through alterations in upstream Wnt and




Fig. 1 GSK3 and its role in AD. Over-activity of GSK3 caused either by aberrant Wnt or insulin signaling in sporadic AD cases or through familial mutations in PS or APP in FAD, might play an integral role in disease progression. GSK3 mediates the hyper-phosphorylation of tau, the increased production of A β from APP (via β and γ secretase-mediated cleavage) and results in impairments in learning and memory and could potentially heighten microglial-mediated inflammatory responses in the local vicinity of A β plaques.

insulin signalling pathway intermediates. The low-density lipoprotein receptor related Protein 6 (LRP6), a co-receptor for Wnt signaling, has recently been identified as a risk gene for late onset AD in apolipoprotein E4-e4 negative individuals (De Ferrari *et al.* 2007), implicating aberrant Wnt signalling in AD pathology. In addition, an association of AD with diabetes and insulin resistance has been reported (Biessels and Kappelle 2005) and genetic studies find insulin signaling genes to be susceptibility loci for AD (Hamilton *et al.* 2007; Reiman *et al.* 2007).

GSK3 and memory

Suppression of Wnt or PI3-kinase signaling impairs long term potentiation (LTP), the best characterized correlate of learning and memory (Sanna *et al.* 2002; Chen *et al.* 2006). GSK3 is negatively regulated by both the Wnt and insulin pathways and inhibition of GSK3 β follows the induction of LTP in wild-type mice (Hooper *et al.* 2007; Peineau *et al.* 2007) suggesting that GSK3 β might mediate the effects of insulin and Wnt on LTP. Accordingly, over-expression of GSK3 β in mice prevents the induction of LTP (Hooper *et al.* 2007) and causes a decrease in spatial learning (Hernandez *et al.* 2002). Inhibitors of GSK3 β have also been shown to block long-term depression (LTD) and GSK3 β activity is enhanced during LTD (Peineau *et al.* 2007). Thus, it would appear that GSK3 β is critical for the

induction of memory formation, switching off LTD and allowing LTP to occur.

Many downstream substrates of GSK3 are involved in synaptic remodeling, which is a vital process required for the proper establishment of connections during memory formation. Adenomatous polyposis coli a synaptic scaffolding protein (Rubinfeld *et al.* 1996) and collapsin response mediator proteins (CRMPs) are known to influence growth cone dynamics and are hyper-phosphorylated in A β plaques (Cole *et al.* 2004). GSK3 also phosphorylates and inhibits cAMP responsive element-binding protein (Bullock and Habener 1998; Hansen *et al.* 2004), a universal modulator of memory. Moreover, GSK3 promotes actin and tubulin assembly (Koivisto *et al.* 2004), processes required for synaptic reorganization during memory formation. We propose, therefore, that GSK3 acts as a gate through which LTP and memory are established. Considering, GSK3 activity is increased in AD, memory failure in this disorder might be attributable to the inhibition of LTP with neuronal loss ensuing as the disease progresses.

GSK3 and tau phosphorylation

Both GSK3 β and GSK3 α (Hanger *et al.* 1992; Ishiguro *et al.* 1992; Lovestone *et al.* 1994; Cho and Johnson 2003; Asuni *et al.* 2006) induce the hyper-phosphorylation of tau at both primed and non-primed phosphorylation sites, *in vitro* and in

cell culture models of neurodegeneration, implicating GSK3 as an important tau-kinase possibly involved in the formation of NFTs *in vivo*. Consistent with this, GSK3 β transgenic mice display tau hyper-phosphorylation and neurodegeneration (Lucas *et al.* 2001) and chronic lithium (GSK3 inhibitor) treatment prevents tau hyper-phosphorylation and NFT formation in double transgenic mice over-expressing GSK3 β and tau (harboring a triple mutation associated with frontotemporal dementia and parkinsonism linked to chromosome 17), although reversal of pre-formed tangles was not observed (Engel *et al.* 2006). Similarly, double-transgenic *Drosophila* over-expressing tau and *shaggy*, the *Drosophila* form of GSK3, exhibit neuronal impairment and tau pathology (Mudher *et al.* 2004).

Insulin transiently increases tau phosphorylation in human neuroblastoma cells, but this is soon followed by a reduction in tau phosphorylation, which correlates with the activation and subsequent inhibition of GSK3 (Lesort *et al.* 1999). Dickkopf, a negative regulator of Wnt signaling also promotes tau phosphorylation and neurodegeneration through the activation of GSK3 (Caricasole *et al.* 2004) and Dickkopf is up-regulated in AD. Furthermore, PS-1 binds both GSK3 β and tau, and mutant forms of PS-1, associated with FAD, bind GSK3 β more effectively resulting in increased tau phosphorylation (Takashima *et al.* 1998). PS-1 has been shown to inactivate GSK3 through PI3-kinase/Akt signaling preventing tau phosphorylation and apoptosis. Interestingly, PS-1 FAD mutations inhibit PS-1-dependent PI3-kinase/Akt signaling, facilitating GSK3 activity and thus tau hyper-phosphorylation. This is one potential mechanism through which FAD mutations might lead to accelerated disease progression through secondary aberrations in GSK3 activity (Baki *et al.* 2004).

GSK3 and A β production

GSK3 α , but not GSK3 β , has been shown to regulate APP cleavage resulting in the increased production of A β (Sun *et al.* 2002; Phiel *et al.* 2003). Exposure of neurones to A β increases GSK3 β activity through the inhibition of PI3-kinase signalling and blockade of either GSK3 β expression or activity prevents A β -induced neurodegeneration (Takashima *et al.* 1993, 1996; Alvarez *et al.* 1999). Although heightened GSK3 activity is not the primary cause of disease in this scenario, increased GSK3 activity would serve to augment A β production and in turn tau hyper-phosphorylation and neuronal degeneration in both FAD and sporadic cases, in line with the amyloid cascade hypothesis of AD.

Insulin signaling, possibly acting through the suppression of GSK3 activity, has also been shown to exert a beneficial effect on APP and amyloid processing. Insulin increases the expression of the A β -protease, insulin degrading enzyme (IDE) (Zhao *et al.* 2004) and enhances the secretion of sAPP α , which results from the non-amyloidogenic α -secretase-mediated cleavage of APP (Solano *et al.* 2000). We also

note with great interest the finding that in people with AD, insulin given through the intranasal route favorably alters the A β 40/42 ratio and improves cognition (Reger *et al.* 2007).

GSK3 and inflammation

As well as being implicated in the core pathogenic events of AD – the increased formation of A β , tau hyper-phosphorylation and memory impairment – GSK3 might also play a role in other processes thought to impact on the amyloid cascade. Foremost amongst these are inflammatory processes. There is a growing body of evidence to suggest that inflammation plays an important role in AD. Microglia are known to accumulate around A β plaques in AD (Christie *et al.* 1996; Joshi and Crutcher 1998; Stalder *et al.* 1999) and there is increased expression of inflammatory mediators in AD brain tissue (McGeer and McGeer 1996). Moreover, Fc-dependent engagement of microglia is thought to be one mechanism through which A β immunotherapy operates. This treatment strategy has proven successful in improving cognitive function and reducing A β plaque burden in both animal models of AD and in human AD patients. However, phase II clinical trials were aborted as some patients developed symptoms of brain inflammation resembling encephalitis or meningitis following injection with A β (Robinson *et al.* 2003; Schenk *et al.* 2005). In the periphery, the regulation of GSK3 activity is critical for inflammatory cell differentiation, inflammatory cell migration and the secretion of pro-inflammatory cytokines (Woodgett and Ohashi 2005; Jope *et al.* 2007; Rodionova *et al.* 2007). However, little is known about the function of GSK3 in the cerebral inflammatory response, which is predominantly mediated by microglia. If, as we discuss above, GSK3 regulation is aberrant in AD brain, then this might impact upon the cerebral inflammatory response leading to the sustained secretion of neuro-toxic inflammatory mediators by microglia, in turn causing by-stander damage to neighboring neurons and contributing to neurodegenerative processes.

Concluding remarks

There is then substantial data strongly implicating GSK3 in the pathogenesis of AD. GSK3 activity and/or protein levels are increased in afflicted individuals with AD and cell biological, epidemiological and genetic evidence points to an association between AD and pathways that regulate GSK3. We postulate these pathways augment GSK3 activity through secondary changes in both regulatory Ser and Tyr phosphorylation, mediated either directly or through alterations in the insulin and/or Wnt signaling cascades or indeed through other pathways that converge on GSK3.

In various cell culture, invertebrate and mammalian models of AD increasing GSK3 activity leads to the hyper-phosphorylation of tau, increased A β generation and deficits in learning and memory accompanied with neurodegeneration. Most importantly inhibiting GSK3 activity reverses

some of the pathological effects of over-expression of mutated APP and tau in the best available models of AD (Noble *et al.* 2005; Rockenstein *et al.* 2007). Our 'GSK3 hypothesis of AD' integrates and extends the well established 'amyloid cascade hypothesis of AD' incorporating the known key molecular events and linking these with outcomes such as memory impairment and inflammation. If correct, then this hypothesis strongly implicates GSK3 inhibitors as a novel treatment strategy for AD.

References

- Alvarez G., Munoz-Montano J. R., Satrustegui J., Avila J., Bogonez E. and az-Nido J. (1999) Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. *FEBS Lett.* **453**, 260–264.
- Anderton B. H., Betts J., Blackstock W. P. *et al.* (2001) Sites of phosphorylation in tau and factors affecting their regulation. *Biochem. Soc. Symp.* **67**, 73–80.
- Asuni A. A., Hooper C., Reynolds C. H., Lovestone S., Anderton B. H. and Killick R. (2006) GSK3 α exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. *Eur. J. Neurosci.* **24**, 3387–3392.
- Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R. and Robakis N. K. (2004) PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. *EMBO J.* **23**, 2586–2596.
- Bhat R. V., Shanley J., Correll M. P., Fieles W. E., Keith R. A., Scott C. W. and Lee C. M. (2000) Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3 β in cellular and animal models of neuronal degeneration. *Proc. Natl. Acad. Sci USA* **97**, 11074–11079.
- Biessels G. J. and Kappelle L. J. (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? *Biochem. Soc. Trans.* **33**, 1041–1044.
- Bijur G. N. and Jope R. S. (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 β . *J. Biol. Chem.* **276**, 37436–37442.
- Blalock E. M., Geddes J. W., Chen K. C., Porter N. M., Markesbery W. R. and Landfield P. W. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. *PNAS* **101**, 2173–2178.
- Brion J. P., Anderton B. H., Authalet M., Dayanandan R., Leroy K., Lovestone S., Octave J. N., Pradier L., Touchet N. and Treppe G. (2001) Neurofibrillary tangles and tau phosphorylation. *Biochem. Soc. Symp.* **0**, 81–88.
- Bullock B. P. and Habener J. F. (1998) Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. *Biochemistry* **37**, 3795–3809.
- Caricasole A., Copani A., Caraci F., Aronica E., Rozemuller A. J., Caruso A., Storto M., Gaviraghi G., Terstappen G. C. and Nicoletti F. (2004) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. *J. Neurosci.* **24**, 6021–6027.
- Chen J., Park C. S. and Tang S. J. (2006) Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. *J. Biol. Chem.* **281**, 11910–11916.
- Cho J. H. and Johnson G. V. (2003) Glycogen synthase kinase 3 β phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. *J. Biol. Chem.* **278**, 187–193.
- Christie R. H., Freeman M. and Hyman B. T. (1996) Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. *Am. J. Pathol.* **148**, 399–403.
- Cole A. R., Knebel A., Morrice N. A., Robertson L. A., Irving A. J., Connolly C. N. and Sutherland C. (2004) GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. *J. Biol. Chem.* **279**, 50176–50180.
- Dale T. C. (1998) Signal transduction by the Wnt family of ligands. *Biochem. J.* **329** (Pt 2), 209–223.
- De Ferrari G. V., Papassotiropoulos A., Biechele T. *et al.* (2007) Common genetic variation within the low-density lipoprotein receptor-related Protein 6 and late-onset Alzheimer's disease. *PNAS* **104**, 9434–9439.
- Doble B. W. and Woodgett J. R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. *J. Cell Sci.* **116**, 1175–1186.
- Doble B. W., Patel S., Wood G. A., Kockeritz L. K. and Woodgett J. R. (2007) Functional redundancy of GSK-3 α and GSK-3 β in Wnt/ β -catenin signaling shown by using an allelic series of embryonic stem cell lines. *Dev. Cell* **12**, 957–971.
- Engel T., Goni-Oliver P., Lucas J. J., Avila J. and Hernandez F. (2006) Chronic lithium administration to FTDP-17 tau and GSK-3 β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. *J. Neurochem.* **99**, 1445–1455.
- Hamilton G., Proitsi P., Jehu L., Morgan A., Williams J., O'Donovan M. C., Owen M. J., Powell J. F. and Lovestone S. (2007) Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPAR γ as susceptibility loci. *Am. J. Med Genet B Neuropsychiatr. Genet* **144**, 508–516.
- Hanger D. P., Hughes K., Woodgett J. R., Brion J. P. and Anderton B. H. (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. *Neurosci. Lett.* **147**, 58–62.
- Hansen T. O., Rehfeld J. F. and Nielsen F. C. (2004) GSK-3 β reduces cAMP-induced cholecystokinin gene expression by inhibiting CREB binding. *Neuroreport* **15**, 841–845.
- Hardy J. (2006) A hundred years of Alzheimer's disease research. *Neuron* **52**, 3–13.
- Hernandez F., Borrell J., Guaza C., Avila J. and Lucas J. J. (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3 β in the brain but do not form tau filaments. *J. Neurochem.* **83**, 1529–1533.
- Hoeflich K. P., Luo J., Rubie E. A., Tsao M. S., Jin O. and Woodgett J. R. (2000) Requirement for glycogen synthase kinase-3 β in cell survival and NF- κ B activation. *Nature* **406**, 86–90.
- Hooper C., Markevich V., Plattner F. *et al.* (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. *Eur. J. Neurosci.* **25**, 81–86.
- Hoshi M., Takashima A., Noguchi K., Murayama M., Sato M., Kondo S., Saitoh Y., Ishiguro K., Hoshino T. and Imahori K. (1996) Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3 β in brain. *Proc. Natl. Acad. Sci USA* **93**, 2719–2723.
- Huelsken J. and Behrens J. (2002) The Wnt signalling pathway. *J. Cell Sci.* **115**, 3977–3978.
- Hye A., Kerr F., Archer N., Foy C., Poppe M., Brown R., Hamilton G., Powell J., Anderton B. and Lovestone S. (2005) Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. *Neurosci. Lett.* **373**, 1–4.

- Imahori K. and Uchida T. (1997) Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. *J Biochem. (Tokyo)* **121**, 179–188.
- Ishiguro K., Omori A., Takamatsu M., Sato K., Arioka M., Uchida T. and Imahori K. (1992) Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. *Neurosci. Lett.* **148**, 202–206.
- Jope R. S., Yuskaitis C. J. and Beurel E. (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. *Neurochem. Res.* **32**, 577–595.
- Joshi S. N. and Crutcher K. A. (1998) Rat microglia exhibit increased density on Alzheimer's plaques in vitro. *Exp. Neurol.* **149**, 42–50.
- Koivisto L., Hakkinen L., Matsumoto K., McCulloch C. A., Yamada K. M. and Larjava H. (2004) Glycogen synthase kinase-3 regulates cytoskeleton and translocation of Rac1 in long cellular extensions of human keratinocytes. *Exp. Cell Res.* **293**, 68–80.
- Leroy K., Yilmaz Z. and Brion J. P. (2007) Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. *Neuropathol. Appl. Neurobiol.* **33**, 43–55.
- Lesort M., Jope R. S. and Johnson G. V. (1999) Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. *J. Neurochem.* **72**, 576–584.
- Lizcano J. M. and Alessi D. R. (2002) The insulin signalling pathway. *Curr. Biol.* **12**, R236–R238.
- Lovestone S., Reynolds C. H., Latimer D., Davis D. R., Anderton B. H., Gallo J. M., Hanger D., Mulot S., Marquardt B. and Stabel S. (1994) Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. *Curr. Biol.* **4**, 1077–1086.
- Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R. and Avila J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO J.* **20**, 27–39.
- MacAulay K., Doble B. W., Patel S., Hansotia T., Sinclair E. M., Drucker D. J., Nagy A. and Woodgett J. R. (2007) Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. *Cell Metab* **6**, 329–337.
- Mateo I., Infante J., Llorca J., Rodriguez E., Berciano J. and Combarros O. (2006) Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. *Dement. Geriatr. Cogn Disord.* **21**, 228–232.
- McGeer P. L. and McGeer E. G. (1996) Anti-inflammatory drugs in the fight against Alzheimer's disease. *Ann. NY Acad. Sci.* **777**, 213–220.
- Mudher A., Shepherd D., Newman T. A. *et al.* (2004) GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. *Mol. Psychiatry* **9**, 522–530.
- Mukai F., Ishiguro K., Sano Y. and Fujita S. C. (2002) Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. *J. Neurochem.* **81**, 1073–1083.
- Noble W., Planel E., Zehr C. *et al.* (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. *Proc. Natl. Acad. Sci. USA* **102**, 6990–6995.
- Nusse R. (2005) Wnt signaling in disease and in development. *Cell Res.* **15**, 28–32.
- Pei J. J., Tanaka T., Tung Y. C., Braak E., Iqbal K. and Grundke-Iqbal I. (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. *J. Neuropathol. Exp. Neurol.* **56**, 70–78.
- Pei J. J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B. and Cowburn R. F. (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. *J. Neuropathol. Exp. Neurol.* **58**, 1010–1019.
- Peineau S., Taghibiglou C., Bradley C. *et al.* (2007) LTP Inhibits LTD in the Hippocampus via Regulation of GSK3beta. *Neuron* **53**, 703–717.
- Phiel C. J., Wilson C. A., Lee V. M. and Klein P. S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. *Nature* **423**, 435–439.
- Reger M. A., Watson G. S., Green P. S. *et al.* (2007) Intranasal insulin improves cognition and modulates {beta}-amyloid in early AD. *Neurology* (Epub ahead of print).
- Reiman E. M., Webster J. A., Myers A. J. *et al.* (2007) GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. *Neuron* **54**, 713–720.
- Robinson S. R., Bishop G. M. and Munch G. (2003) Alzheimer vaccine: amyloid-beta on trial. *Bioessays* **25**, 283–288.
- Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J. B., Crews L. and Masliah E. (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. *J. Neurosci.* **27**, 1981–1991.
- Rodionova E., Conzelmann M., Maraskovsky E., Hess M., Kirsch M., Giese T., Ho A. D., Zoller M., Dreger P. and Luft T. (2007) GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. *Blood* **109**, 1584–1592.
- Rubinfeld B., Albert I., Porfiri E., Fiol C., Munemitsu S. and Polakis P. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. *Science* **272**, 1023–1026.
- Saltiel A. R. and Kahn C. R. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* **414**, 799–806.
- Sanna P. P., Cammalleri M., Berton F., Simpson C., Lutjens R., Bloom F. E. and Francesconi W. (2002) Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region. *J. Neurosci.* **22**, 3359–3365.
- Schaffer B., Wiedau-Pazos M. and Geschwind D. H. (2003) Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues. *Gene* **302**, 73–81.
- Schenk D. B., Seubert P., Grundman M. and Black R. (2005) A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. *Neurodegener. Dis.* **2**, 255–260.
- Solano D. C., Sironi M. A. R. I., Bonfina C. L. A. U., Solerte S. B., Govoni S. T. E. F. and RACCHI M. A. R. C. (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidylinositol 3 kinase-dependent pathway. *FASEB J.* **14**, 1015–1022.
- Stalder M., Phinney A., Probst A., Sommer B., Staufenbiel M. and Jucker M. (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. *Am. J. Pathol.* **154**, 1673–1684.
- Sun X., Sato S., Murayama O., Murayama M., Park J.-M., Yamaguchi H. and Takashima A. (2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. *Neurosci. Lett.* **321**, 61–64.
- Swatton J. E., Sellers L. A., Faull R. L. M., Holland A., Iritani S. and Bahn S. (2004) Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. *Eur. J. Neurosci.* **19**, 2711–2719.
- Takashima A., Noguchi K., Sato K., Hoshino T. and Imahori K. (1993) Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. *Proc. Natl. Acad. Sci. USA* **90**, 7789–7793.
- Takashima A., Noguchi K., Michel G., Mercken M., Hoshi M., Ishiguro K. and Imahori K. (1996) Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidylinositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. *Neurosci. Lett.* **203**, 33–36.

- Takashima A., Murayama M., Murayama O. *et al.* (1998) Presenilin 1 associates with glycogen synthase kinase-3 β and its substrate tau. *Proc. Natl. Acad. Sci USA* **95**, 9637–9641.
- Troussard A. A., Tan C., Yoganathan T. N. and Dedhar S. (1999) Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. *Mol. Cell. Biol.* **19**, 7420–7427.
- Turenne G. A. and Price B. D. (2001) Glycogen synthase kinase-3 β phosphorylates serine 33 of p53 and activates p53's transcriptional activity. *BMC Cell Biol.* **2**, 12.
- Vehmas A. K., Kawas C. H., Stewart W. F. and Troncoso J. C. (2003) Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. *Neurobiol. Aging* **24**, 321–331.
- Welsh G. I. and Proud C. G. (1993) Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. *Biochem. J.* **294** (Pt 3), 625–629.
- Woodgett J. R. and Ohashi P. S. (2005) GSK3: an in-Toll-erant protein kinase? *Nat. Immunol.* **6**, 751–752.
- Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C. A. and Imahori K. (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 β and cyclin-dependent kinase 5, a component of TPK II. *Acta Neuropathol. (Berl)* **92**, 232–241.
- Zhao L., Teter B., Morihara T., Lim G. P., Ambegaokar S. S., Ubeda O. J., Frautschy S. A. and Cole G. M. (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. *J. Neurosci.* **24**, 11120–11126.